Exact Sciences Raises $56M in IPO, But Analysts Still Cautious | GenomeWeb

NEW YORK, Jan 31 – Worried that Wall Street had completely turned its back on genomics companies, some investors — and executives — may be breathing a sigh of relief after applied genomics company Exact Sciences raised $56 million in an initial public offering on Wednesday.

In appraising the IPO climate some analysts noted that since the end of December, stock prices have begun to creep up out of the cellar, giving investors and companies alike a bit more confidence.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.